Bladder Cancer

Findings from a preplanned analysis assessing 2 clinical trials of bempegaldesleukin plus nivolumab in renal cell carcinoma and bladder cancer led to a decision to end the combination’s global clinical development program and discontinue all other ongoing clinical trials.

European patients with locally advanced or metastatic urothelial cancer can now receive treatment with enfortumab vedotin following treatment with a platinum-containing regimen and a PD-(L)1 inhibitor.

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).

The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.

At the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Daniel P. Petrylak, MD, reviews the current systemic therapy treatment paradigm in metastatic urothelial carcinoma.

A significant improvement in overall survival was observed in patients with high-risk bladder cancer who achieved radical cystectomy–pentafecta.

Adding olaparib to durvalumab did not significantly improve progression-free survival for patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Data from cohort H of the EV-103 study highlighted the promising antitumor activity of neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer who are cisplatin-ineligible.

Patients with checkpoint inhibitor–naïve metastatic urothelial cancer appeared to experience promising anti-tumor activity following treatment with second line sacituzumab govitecan and pembrolizumab.

Patients with previously treated metastatic urothelial carcinoma or renal cell carcinoma experienced promising benefit from treatment with niraparib and cabozantinib.

Despite missing the trial primary end point of overall survival improvement at 1 year, data for avelumab in cisplatin-ineligible, PD-L1–positive advanced urothelial cancer demonstrated superior responses and disease control rates.

Frontline avelumab plus best supportive care as maintenance showed an improvement in overall survival vs best supportive care alone in patients with advanced urothelial cancer treated after chemotherapy.

Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.

Research suggests age-standardized incidence and death rates for patients with bladder cancer decreased globally between 1990 and 2019.

Patients with bladder cancer reported improvements in physical and social scores following radical cystectomy, although body image and sexual functioning scores decreased.

Patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin may benefit from treatment with CG0070 plus pembrolizumab.

Daniel P. Petrylak, MD, spoke with CancerNetwork® about the results of the TROPHY U-01 study examining sacituzumab govitecan in the treatment of patients with metastatic urothelial carcinoma following failure of platinum-based chemotherapy.

Treatment with induction UGN-101 produced durable responses in patients with low-grade upper tract urothelial carcinoma.

Patients with BCG-unresponsive non-muscle invasive bladder cancer may benefit from treatment with avelumab and BCG induction therapy